- Home
- A-Z Publications
- Annual Review of Immunology
- Previous Issues
- Volume 21, 2003
Annual Review of Immunology - Volume 21, 2003
Volume 21, 2003
- Review Articles
-
-
-
Tolerogenic Dendritic Cells*
Vol. 21 (2003), pp. 685–711More Less▪ AbstractDendritic cells (DCs) have several functions in innate and adaptive immunity. In addition, there is increasing evidence that DCs in situ induce antigen-specific unresponsiveness or tolerance in central lymphoid organs and in the periphery. In the thymus DCs generate tolerance by deleting self-reactive T cells. In peripheral lymphoid organs DCs also induce tolerance to antigens captured by receptors that mediate efficient uptake of proteins and dying cells. Uptake by these receptors leads to the constitutive presentation of antigens on major histocompatibility complex (MHC) class I and II products. In the steady state the targeting of DC antigen capture receptors with low doses of antigens leads to deletion of the corresponding T cells and unresponsiveness to antigenic rechallenge with strong adjuvants. In contrast, if a stimulus for DC maturation is coadministered with the antigen, the mice develop immunity, including interferon-γ-secreting effector T cells and memory T cells. There is also new evidence that DCs can contribute to the expansion and differentiation of T cells that regulate or suppress other immune T cells. One possibility is that distinct developmental stages and subsets of DCs and T cells can account for the different pathways to peripheral tolerance, such as deletion or suppression. We suggest that several clinical situations, including autoimmunity and certain infectious diseases, can be influenced by the antigen-specific tolerogenic role of DCs.
-
-
-
-
Molecular Mechanisms RegulatinG Th1 Immune Responses
Vol. 21 (2003), pp. 713–758More LessThe T helper lymphocyte is responsible for orchestrating the appropriate immune response to a wide variety of pathogens. The recognition of the polarized T helper cell subsets Th1 and Th2 has led to an understanding of the role of these cells in coordinating a variety of immune responses, both in responses to pathogens and in autoimmune and allergic disease. Here, we discuss the mechanisms that control lineage commitment to the Th1 phenotype. What has recently emerged is a rich understanding of the cytokines, receptors, signal transduction pathways, and transcription factors involved in Th1 differentiation. Although the picture is still incomplete, the basic pathways leading to Th1 differentiation can now be understood in in vitro and a number of infection and disease models.
-
-
-
Biology of Hematopoietic Stem Cells and Progenitors: Implications for Clinical Application
Vol. 21 (2003), pp. 759–806More Less▪ AbstractStem cell biology is scientifically, clinically, and politically a current topic. The hematopoietic stem cell, the common ancestor of all types of blood cells, is one of the best-characterized stem cells in the body and the only stem cell that is clinically applied in the treatment of diseases such as breast cancer, leukemias, and congenital immunodeficiencies. Multicolor cell sorting enables the purification not only of hematopoietic stem cells, but also of their downstream progenitors such as common lymphoid progenitors and common myeloid progenitors. Recent genetic approaches including gene chip technology have been used to elucidate the gene expression profile of hematopoietic stem cells and other progenitors. Although the mechanisms that control self-renewal and lineage commitment of hematopoietic stem cells are still ambiguous, recent rapid advances in understanding the biological nature of hematopoietic stem and progenitor cells have broadened the potential application of these cells in the treatment of diseases.
-
-
-
Does the Immune System See Tumors as Foreign or Self?
Vol. 21 (2003), pp. 807–839More LessGiven the vast number of genetic and epigenetic changes associated with carcinogenesis, it is clear that tumors express many neoantigens. A central question in cancer immunology is whether recognition of tumor antigens by the immune system leads to activation (i.e., surveillance) or tolerance. Paradoxically, while strong evidence exists that specific immune surveillance systems operate at early stages of tumorigenesis, established tumors primarily induce immune tolerance. A unifying hypothesis posits that the fundamental processes of cancer progression, namely tissue invasion and metastasis, are inherently proinflammatory and thus activating for innate and adaptive antitumor immunity. To elude immune surveillance, tumors must develop mechanisms that block the elaboration and sensing of proinflammatory danger signals, thereby shifting the balance from activation to tolerance induction. Elucidation of these mechanisms provides new strategies for cancer immunotherapy.
-
-
-
B Cell Chronic Lymphocytic Leukemia: Lessons Learned from Studies of the B Cell Antigen Receptor
Vol. 21 (2003), pp. 841–894More LessB cell chronic lymphocytic leukemia (B-CLL) is an accumulative disease of slowly proliferating CD5+ B lymphocytes that develops in the aging population. Whereas some patients with B-CLL have an indolent course and die after many years from unrelated causes, others progress very rapidly and succumb within a few years from this currently incurable leukemia. Over the past decade studies of the structure and function of the B cell antigen receptor (BCR) used by these leukemic cells have helped redefine the nature of this disease. In this review we summarize and reinterpret several aspects of these BCR-related studies and how they might relate to the disease. In particular, we address the ability of antigens to select out and drive B cell clones from the normal state to overt leukemic cells by binding to BCRs that are relatively unique and characteristic of B-CLL cells. The differential capacity of some B-CLL cases to continue to transduce signals through the BCR during the leukemic phase and the consequences for the in vivo biology of the leukemic clone is also considered. Finally, we discuss current and emerging views of the cellular origin of B-CLL cells and the differentiation pathways down which we believe these cells progress.
-
Previous Volumes
-
Volume 41 (2023)
-
Volume 40 (2022)
-
Volume 39 (2021)
-
Volume 38 (2020)
-
Volume 37 (2019)
-
Volume 36 (2018)
-
Volume 35 (2017)
-
Volume 34 (2016)
-
Volume 33 (2015)
-
Volume 32 (2014)
-
Volume 31 (2013)
-
Volume 30 (2012)
-
Volume 29 (2011)
-
Volume 28 (2009)
-
Volume 27 (2009)
-
Volume 25 (2007)
-
Volume 24 (2006)
-
Volume 26 (2005)
-
Volume 23 (2005)
-
Volume 22 (2004)
-
Volume 21 (2003)
-
Volume 20 (2002)
-
Volume 19 (2001)
-
Volume 18 (2000)
-
Volume 17 (1999)
-
Volume 16 (1998)
-
Volume 15 (1997)
-
Volume 14 (1996)
-
Volume 13 (1995)
-
Volume 12 (1994)
-
Volume 11 (1993)
-
Volume 10 (1992)
-
Volume 9 (1991)
-
Volume 8 (1990)
-
Volume 7 (1989)
-
Volume 6 (1988)
-
Volume 5 (1987)
-
Volume 4 (1986)
-
Volume 3 (1985)
-
Volume 2 (1984)
-
Volume 1 (1983)
-
Volume 0 (1932)